170 related articles for article (PubMed ID: 27766004)
1. Quantitative and Qualitative Analysis of Circulating Cell-Free DNA Can Be Used as an Adjuvant Tool for Prostate Cancer Screening: A Meta-Analysis.
Yin C; Luo C; Hu W; Ding X; Yuan C; Wang F
Dis Markers; 2016; 2016():3825819. PubMed ID: 27766004
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
Yang X; Zhang K; Zhang C; Peng R; Sun C
BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis.
Li B; Pu K; Ge L; Wu X
Gene; 2019 Sep; 714():143993. PubMed ID: 31330238
[TBL] [Abstract][Full Text] [Related]
4. Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis.
Zhou Q; Li W; Leng B; Zheng W; He Z; Zuo M; Chen A
PLoS One; 2016; 11(6):e0155495. PubMed ID: 27253331
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.
Zhou Y; Wang C; Zhu H; Lin Y; Pan B; Zhang X; Huang X; Xu Q; Xu Y; Sun Q
PLoS One; 2016; 11(6):e0158143. PubMed ID: 27336598
[TBL] [Abstract][Full Text] [Related]
6. Macrophage inhibitory cytokine 1 biomarker serum immunoassay in combination with PSA is a more specific diagnostic tool for detection of prostate cancer.
Li J; Veltri RW; Yuan Z; Christudass CS; Mandecki W
PLoS One; 2015; 10(4):e0122249. PubMed ID: 25853582
[TBL] [Abstract][Full Text] [Related]
7. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
8. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis.
Lin Z; Neiswender J; Fang B; Ma X; Zhang J; Hu X
Oncotarget; 2017 Apr; 8(16):26625-26636. PubMed ID: 28460452
[TBL] [Abstract][Full Text] [Related]
9. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
[TBL] [Abstract][Full Text] [Related]
10. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
[TBL] [Abstract][Full Text] [Related]
11. Role of Ca 15-3 in patients with biochemically suspected prostate cancer and multiple negative ultrasound-guided prostate biopsies.
Falsaperla M; Morgia G; Giammusso B; Condorelli SV; Saita A; Marchese F; Spampinato A; Motta M
Prostate Cancer Prostatic Dis; 2003; 6(1):45-9. PubMed ID: 12664064
[TBL] [Abstract][Full Text] [Related]
12. Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer.
Schütz E; Akbari MR; Beck J; Urnovitz H; Zhang WW; Bornemann-Kolatzki K; Mitchell WM; Nam RK; Narod SA
Clin Chem; 2015 Jan; 61(1):239-48. PubMed ID: 25348670
[TBL] [Abstract][Full Text] [Related]
13. Quantification of Circulating Free DNA as a Diagnostic Marker in Gall Bladder Cancer.
Kumari S; Tewari S; Husain N; Agarwal A; Pandey A; Singhal A; Lohani M
Pathol Oncol Res; 2017 Jan; 23(1):91-97. PubMed ID: 27475647
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of cell-free DNA in thyroid cancer: A systematic review and meta-analysis.
Hou F; Sun XD; Deng ZY
Medicine (Baltimore); 2023 Feb; 102(7):e32928. PubMed ID: 36800605
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of emerging liquid biomarkers in advanced prostate cancer.
Vandekerkhove G; Chi KN; Wyatt AW
Cancer Genet; 2018 Dec; 228-229():151-158. PubMed ID: 28958406
[TBL] [Abstract][Full Text] [Related]
16. Detection of Loss of Heterozygosity (LOH) Using Circulating Cell-free DNA (cfDNA) by Fluorescence-based Multiplex PCR for Identification of Patients With Prostate Cancer.
Seyedolmohadessin SM; Akbari MT; Nourmohammadi Z; Basiri A; Pourmand G
Appl Immunohistochem Mol Morphol; 2018; 26(10):749-759. PubMed ID: 28362710
[TBL] [Abstract][Full Text] [Related]
17. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy: ready to guide therapy in advanced prostate cancer?
Hegemann M; Stenzl A; Bedke J; Chi KN; Black PC; Todenhöfer T
BJU Int; 2016 Dec; 118(6):855-863. PubMed ID: 27430478
[TBL] [Abstract][Full Text] [Related]
19. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
20. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
Steuber T; Vickers A; Haese A; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
Int J Cancer; 2007 Apr; 120(7):1499-504. PubMed ID: 17205511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
